Leveraging microenvironmental synthetic lethalities to treat cancer
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Treatment resistance leads to cancer patient mortality. Therapeutic approaches that employ synthetic lethality to target mutational vulnerabilities in key tumor cell signaling pathways have proven effective in overcoming therapeutic resistance in some cancers. Yet, tumors are organs composed of malignant cells residing within a cellular and noncellular stroma. Tumor evolution and resistance to anticancer treatment are mediated through a dynamic and reciprocal dialogue with the tumor microenvironment (TME). Accordingly, expanding tumor cell synthetic lethality to encompass contextual synthetic lethality has the potential to eradicate tumors by targeting critical TME circuits that promote tumor progression and therapeutic resistance. In this Review, we summarize current knowledge about the TME and discuss its role in treatment. We outline the concept of tumor cell-specific synthetic lethality and describe therapeutic approaches to expand this paradigm to leverage TME synthetic lethality to improve cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer‐associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Yet many tumors are abnormally and poorly vascularized, which causes nutrient-poor and hypoxic regions within tumors (101).”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Overview of the tumor microenvironment and drug resistance Tumors are composed of a population of cancer cells that are genetically, phenotypically, and spatially heterogeneous, and this heterogeneity correlates with drug resistance (11, 12).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“PARP, BRCA1, and BRCA2 contribute to DNA repair, making cancer cells carrying BRCA mutations more sensitive to PARP inhibitors (97, 98).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Self-citationA framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 2×
“Mesenchymal fibroblasts transdifferentiate into cancer-associated fibroblasts (CAFs) and are the primary cell type that deposit, remodel, and cross-link the interstitial ECM (23).”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“While complete loss of MHC class I marks cancer cells for destruction by NK cells (72), downregulation of MHC class I proteins through lysosomal degradation (73) and allelic loss (74, 75) can dampen immune recognition of cancer cells and decrease response to checkpoint inhibitors (73, 76).”
BackgroundThe Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527 · cited 1×
“ECM-dense regions within tumors can also present ECM-bound immune-inhibitory cytokines that compromise the efficacy of cytotoxic and immune therapies (30).”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“Increased glycolysis by cancer cells acidifies the TME by increasing the concentration of lactate, which stimulates differentiation of macrophages into an immunosuppressive state (91).”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Self-citationHypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Debulking hyaluronan with hyaluronidase improves therapeutic response to gemcitabine by enhancing vascularity in a PDAC mouse model (142).”
BackgroundBissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 3×
“Resistance to antitumor treatment can arise either from the emergence of individual tumor cells that harbor mutations that provide survival and proliferative advantages to individual tumor cells or from TME factors that provide context-dependent resistance cues (5).”
BackgroundStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647 · cited 1×
“The FDA-approved iron deficiency nanoparticle drug ferumoxytol induces reactive oxygen species–mediated cytotoxic activities in TAMs toward cancer cells that decrease tumor growth and metastatic burden in multiple mouse models (127).”
BackgroundAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“There are regions of abnormal and poor vascularization in tumors such that some cancer cells experience low nutrient and hypoxic conditions (13, 14).”
BackgroundSwann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · cited 1×
“1172/JCI143765 and lung cancer, but has not found success in multiple tumor types (71).”
BackgroundCD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Integrins as biomechanical sensors of the microenvironment
Kechagia, J. Z., Ivaska, J., & Roca-Cusachs, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0134-2 · Cited by 1,311
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.350 · Cited by 1,204
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122 · cited 1×
“These Siglec receptors have cytosolic immunoreceptor tyrosine-based inhibition motif (ITIM) domains that lead to immune suppression and block cytotoxic reactions toward the hypersialylated cancer cells (86).”
BackgroundRodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Acerbi, I., Cassereau, L., Dean, I., Shi, Q., Au, A., Park, C., Chen, Y. Y., Liphardt, J., Hwang, E. S., & Weaver, V. M. (2015) · Integrative Biology · doi:10.1039/c5ib00040h · Cited by 1,059
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In both breast cancer patients and mouse models, a type I interferon response improves efficacy of doxorubicin treatment, which is produced by dying cancer cells and recruited myeloid cells (60).”
BackgroundNatural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
The single-cell pathology landscape of breast cancer
Jackson, H. W., Fischer, J. R., Zanotelli, V. R. T., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., Muenst, S., Varga, Z., Weber, W. P., et al. (2020) · Nature · doi:10.1038/s41586-019-1876-x · Cited by 900
Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer
Cubillos-Ruiz, J. R., Bettigole, S. E., & Glimcher, L. H. (2017) · Cell · doi:10.1016/j.cell.2016.12.004 · Cited by 895
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 855
Weaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Mendillo, M. L., Santagata, S., Koeva, M., Bell, G. W., Hu, R., Tamimi, R. M., Fraenkel, E., Ince, T. A., Whitesell, L., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.031 · Cited by 694
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Synthetic lethality and cancer
O'Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 658
Innate Immune Training of Granulopoiesis Promotes Anti-tumor Activity
Kalafati, L., Kourtzelis, I., Schulte-Schrepping, J., Li, X., Hatzioannou, A., Grinenko, T., Hagag, E., Sinha, A., Has, C., Dietz, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.058 · Cited by 648
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“For example, depletion of FAP+ CAFs using a FAP vaccine decreases collagen density in tumors and improves response to doxorubicin in mice (135).”
MethodLaklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G. E., Barrett, A. S., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 603
Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 569
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 1×
“Selective modification of monocyte gene expression using the class IIa histone deacetylase (HDAC) inhibitor TMP195 polarizes TAMs to a phagocytic antitumor phenotype that enhances efficacy of carboplatin, paclitaxel, and anti–PD-1 therapies (122).”
MethodIntegrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
Zhang, J., Cunningham, J. J., Brown, J. S., & Gatenby, R. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01968-5 · Cited by 556
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541 · cited 1×
“A CSF-1R antagonist improves response to paclitaxel by blocking macrophage recruitment (64).”
BackgroundChen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1388 · Cited by 485
Leukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Biomimetic amplification of nanoparticle homing to tumors
Simberg, D., Duza, T., Park, J. H., Essler, M., Pilch, J., Zhang, L., Derfus, A. M., Yang, M., Hoffman, R. M., Bhatia, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610298104 · Cited by 471
Casbon, A.-J., Reynaud, D., Park, C., Khuc, E., Gan, D. D., Schepers, K., Passegué, E., & Werb, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424927112 · Cited by 470
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
Krall, J. A., Reinhardt, F., Mercury, O. A., Pattabiraman, D. R., Brooks, M. W., Dougan, M., Lambert, A. W., Bierie, B., Ploegh, H. L., Dougan, S. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3464 · Cited by 442
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Precision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Jandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65899 · Cited by 439
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
Structural cells are key regulators of organ-specific immune responses
Krausgruber, T., Fortelny, N., Fife-Gernedl, V., Senekowitsch, M., Schuster, L. C., Lercher, A., Nemc, A., Schmidl, C., Rendeiro, A. F., Bergthaler, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2424-4 · Cited by 434 · cited 1×
“In many healthy tissues, structural cells (epithelial cells, endothelial cells, and fibroblasts) produce cytokines to recruit immune cells (39).”
BackgroundJaynes, J. M., Sable, R., Ronzetti, M., Bautista, W., Knotts, Z., Abisoye-Ogunniyan, A., Li, D., Calvo, R., Dashnyam, M., Singh, A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax6337 · Cited by 413
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., Luu, T., Li, A. X., Wu, X., Ye, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3567 · Cited by 407
The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy
Scherz-Shouval, R., Santagata, S., Mendillo, M. L., Sholl, L. M., Ben-Aharon, I., Beck, A. H., Dias-Santagata, D., Koeva, M., Stemmer, S. M., Whitesell, L., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.045 · Cited by 386 · cited 1×
“More aggressive tumors express a heat-shock factor 1 (HSF1) transcriptional program in cancer cells and CAFs near necrotic regions (89, 90).”
BackgroundTargeted glycan degradation potentiates the anticancer immune response in vivo
Gray, M. A., Stanczak, M. A., Mantuano, N. R., Xiao, H., Pijnenborg, J. F. A., Malaker, S. A., Miller, C. L., Weidenbacher, P. A., Tanzo, J. T., Ahn, G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0622-x · Cited by 362
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam, K. J., Burnett, C. E., Venida, A., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 328
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
Ali, H. R., Jackson, H. W., Zanotelli, V. R. T., Danenberg, E., Fischer, J. R., Bardwell, H., Provenzano, E., CRUK IMAXT Grand Challenge Team, Ali, H. R., Al Sa’d, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0026-6 · Cited by 306
Maller, O., Drain, A. P., Barrett, A. S., Borgquist, S., Ruffell, B., Zakharevich, I., Pham, T. T., Gruosso, T., Kuasne, H., Lakins, J. N., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-00849-5 · Cited by 298
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120612 · Cited by 296
In situ force mapping of mammary gland transformation
Lopez, J. I., Kang, I., You, W.-K., McDonald, D. M., & Weaver, V. M. (2011) · Integrative Biology · doi:10.1039/c1ib00043h · Cited by 284
Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querzè, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., et al. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1271 · Cited by 282
Syndecans as receptors and organizers of the extracellular matrix
Xian, X., Gopal, S., & Couchman, J. R. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0829-3 · Cited by 264
MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent
Zhou, Z., Qutaish, M., Han, Z., Schur, R. M., Liu, Y., Wilson, D. L., & Lu, Z.-R. (2015) · Nature Communications · doi:10.1038/ncomms8984 · Cited by 260
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Schaue, D., Micewicz, E. D., Ratikan, J. A., Xie, M. W., Cheng, G., & McBride, W. H. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.007 · Cited by 252
Waight, J. D., Hu, Q., Miller, A., Liu, S., & Abrams, S. I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027690 · Cited by 246
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 244
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Miller, M. A., Chandra, R., Cuccarese, M. F., Pfirschke, C., Engblom, C., Stapleton, S., Adhikary, U., Kohler, R. H., Mohan, J. F., Pittet, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal0225 · Cited by 225
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222 · cited 1×
“Inhibition of IL-6 or FGF-2 improved response to anti-VEGF therapy in obese mice (105).”
BackgroundPriem, B., van Leent, M. M. T., Teunissen, A. J. P., Sofias, A. M., Mourits, V. P., Willemsen, L., Klein, E. D., Oosterwijk, R. S., Meerwaldt, A. E., Munitz, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.059 · Cited by 222
Morales, J. K., Kmieciak, M., Knutson, K. L., Bear, H. D., & Manjili, M. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0622-8 · Cited by 214
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 213
Hegan, D. C., Lu, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904783107 · Cited by 209
Weaver, V. M., Lelièvre, S. A., Lakins, J. N., Chrenek, M. A., Jones, J., Giancotti, F. G., Werb, Z., & Bissell, M. J. (2002) · University of North Texas Digital Library (University of North Texas) · doi:10.1016/s1535-6108%2802%2900125-3 · Cited by 208
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures
Demicheli, R., Retsky, M. W., Hrushesky, W. J., & Baum, M. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0999 · Cited by 205
Discoidin domain receptors in disease
Borza, C. M., & Pozzi, A. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.12.002 · Cited by 205
Momin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2614 · Cited by 204
Fang, W. B., Jokar, I., Zou, A., Lambert, D., Dendukuri, P., & Cheng, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365999 · Cited by 197
Oudin, M. J., & Weaver, V. M. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030817 · Cited by 196
Regulation of DNA repair in hypoxic cancer cells
Bindra, R. S., Crosby, M. E., & Glazer, P. M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9061-3 · Cited by 191
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190
Serganova, I., Doubrovin, M., Vider, J., Ponomarev, V., Soghomonyan, S., Beresten, T., Ageyeva, L., Serganov, A., Cai, S., Balatoni, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0842 · Cited by 177
Death in the third dimension: apoptosis regulation and tissue architecture
Zahir, N., & Weaver, V. M. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.12.005 · Cited by 165
Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds
Pilch, J., Brown, D. M., Komatsu, M., Järvinen, T. A. H., Yang, M., Peters, D., Hoffman, R. M., & Ruoslahti, E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511219103 · Cited by 162
Chan, T.-S., Hsu, C.-C., Pai, V. C., Liao, W.-Y., Huang, S.-S., Tan, K.-T., Yen, C.-J., Hsu, S.-C., Chen, W.-Y., Shan, Y.-S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151665 · Cited by 161
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 157
Heindl, A., Sestak, I., Naidoo, K., Cuzick, J., Dowsett, M., & Yuan, Y. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx137 · Cited by 156
Roswall, P., Bocci, M., Bartoschek, M., Li, H., Kristiansen, G., Jansson, S., Lehn, S., Sjölund, J., Reid, S., Larsson, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4494 · Cited by 148
Desai, S., Liu, Z., Yao, J., Patel, N., Chen, J., Wu, Y., Ahn, E. E.-Y., Fodstad, O., & Tan, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.422071 · Cited by 145
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Portela Catani, J. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 137
Vilaboa, N. E., Galán, A., Troyano, A., de Blas, E., & Aller, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909136199 · Cited by 136
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Li, Y., Cao, F., Li, M., Li, P., Yu, Y., Xiang, L., Xu, T., Lei, J., Tai, Y. Y., Zhu, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0938-5 · Cited by 125
Retsky, M., Demicheli, R., Hrushesky, W., Forget, P., Kock, M., Gukas, I., Rogers, R., Baum, M., Sukhatme, V., & Vaidya, J. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990250 · Cited by 121
Hagerling, C., Velozo, H. G., Salari, K., Wang, C., Lin, C., Robles, I., van Gogh, M., Dejmek, A., Jirström, K., & Werb, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907660116 · Cited by 120
Perdicchio, M., Cornelissen, L. A. M., Streng-Ouwehand, I., Engels, S., Verstege, M. I., Boon, L., Geerts, D., van Kooyk, Y., & Unger, W. W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.6822 · Cited by 110
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
Bartal, I. B.-A., Melamed, R., Greenfeld, K., Atzil, S., Glasner, A., Domankevich, V., Naor, R., Beilin, B., Yardeni, I. Z., & Ben‐Eliyahu, S. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.02.010 · Cited by 100
Guerriero, J. L., Ditsworth, D., Catanzaro, J. M., Sabino, G., Furie, M. B., Kew, R. R., Crawford, H. C., & Zong, W.-X. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003267 · Cited by 87
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
Cohen, M., Elkabets, M., Perlmutter, M., Porgador, A., Voronov, E., Apte, R. N., & Lichtenstein, R. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001635 · Cited by 73
A collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54
Tang, X., Sun, G., He, Q., Wang, C., Shi, J., Gao, L., Ye, J., Liang, Y., & Qu, H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02869-0 · Cited by 47
Tumor microvasculature as a barrier to antitumor immunity
Chen, Q., Wang, W., & Evans, S. S. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0425-4 · Cited by 45
Stroma in normal and cancer wound healing
Huet, E., Jaroz, C., Nguyen, H. Q., Belkacemi, Y., de la Taille, A., Stavrinides, V., & Whitaker, H. (2019) · The FEBS Journal · doi:10.1111/febs.14842 · Cited by 42
Sherry, A. D., von Eyben, R., Newman, N. B., Gutkin, P. M., Mayer, I. A., Horst, K. C., Chakravarthy, A. B., & Rafat, M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.11.398 · Cited by 32
Mun, G., Choi, E. A., Lee, Y., & Lee, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2600-3 · Cited by 27
Tiede, S., Kalathur, R. K. R., Lüönd, F., von Allmen, L., Szczerba, B. M., Hess, M., Vlajnic, T., Müller, B., Murillo, J. C., Aceto, N., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01508-4 · Cited by 23
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“The blood and lymphatic ECs, complex collagen fibers and glycoproteins form the ECM, while the cancer-associated fibroblasts (CAFs) and mesenchymal stem cells further assist in ECM remodeling and even chemoresistance [13, 14].”
BackgroundChen, S., Morine, Y., Tokuda, K., Yamada, S., Saito, Y., Nishi, M., Ikemoto, T., & Shimada, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5239 · Cited by 168
Mechanical state transitions in the regulation of tissue form and function
Mao, Y., & Wickström, S. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00719-x · Cited by 162
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., Xiao, Y., Fuh, K. C., Krishnan, V., Enejder, A. M. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146186 · Cited by 138
“Discussion Accumulating evidence suggests that the tumor microenvironment plays an important role in shaping tumor heterogeneity and drug resistance (65).”
BackgroundPancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis
Saab, J. J. A., Dzierozynski, L. N., Jonker, P. B., AminiTabrizi, R., Shah, H., Menjivar, R. E., Scott, A. J., Nwosu, Z. C., Zhu, Z., Chen, R. N., et al. (2023) · eLife · doi:10.7554/elife.81289 · Cited by 88
“, 2007), we anticipate ensuring proper nutrient availability will be critical in the development of more physiologically relevant ex vivo cancer models, which will expand our ability to target cancer by enabling exploitation of microenvironmentally driven therapeutic targets (Metcalf et al., 2021; Sela et al., 2022).”
Background
Metadata
- Authors
- Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Weaver, Valerie M.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-15
- Volume
- 131
- Issue
- 6
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7954586
- OpenAlex
- W3136876771
- Cited by
- 42
- References
- 145
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 5 · 2022: 8 · 2021: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R35CA242447, R01CA227942)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- synthetic lethality, tumor microenvironment, treatment resistance, cancer therapy, tumor stroma, tumor evolution
- MeSH terms
- Synthetic Lethal Mutations, Animals, Female, Humans, Immunotherapy, Male, Neoplasms, Signal Transduction, Disease Progression, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.